Abstract

Acute decompensated heart failure (ADHF) is a major problem among the elderly requiring frequent hospitalizations. Although the vast majority of patients with ADHF require loop diuretic therapy to control symptoms, guidelines for their use have been driven primarily by small nonrandomized trials and observational studies. Ongoing debate has centered on the risks of adverse effects including renal dysfunction and the most appropriate method of administration to minimize these risks. Recently, a large prospective randomized trial, the Diuretic Optimization Strategies Evaluation (DOSE), addressed these issues. This article will review the findings of this trial and the implications for clinical practice.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.